Company intelligence / Profile preview

Kanaph Therapeutics

Seoul, Seoul, South Koreakanaphtx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Kanaph Therapeutics develops next-generation therapeutics for oncology and autoimmune diseases using bi-specific antibodies, small molecules, and bispecific Fc-fusion proteins. Their lead assets target immuno-stimulatory pathways in the tumor microenvironment or inhibit the alternative complement pathway in autoimmune conditions. The company’s pipeline remains largely preclinical with a focus on innovative immune-modulating approaches.

Therapeutic areas: OncologyPulmonologyEndocrinologyImmunology
Modalities: Bi-specific antibodiesSmall moleculesBispecific Fc-fusion proteinsAntibody drug conjugates (ADC)
Industry: Biotech

Drug pipeline

4 assets

KNP-301

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kanaph Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kanaph Therapeutics.

Explore the full profile